Loading provider…
Loading provider…
Medical Oncology Physician in Duarte, CA
NPI: 1285877209Primary Employer
City of Hope Medical - San Bernardino Radiation Oncology
cityofhope.org
HQ Phone
Get M.D. Daneng's Phone Numberphone_androidMobile
Get M.D. Daneng's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardNY State Medical License
CA State Medical License
CA State Medical License
2015 - 2027
NY State Medical License
2012 - 2017

American Board of Internal Medicine
Medical Oncology
Weill Cornell Medicine
weill.cornell.edu
Medical School
Until 2009
Memorial Sloan Kettering Cancer Center
Fellowship • Hematology and Medical Oncology
2012 - 2015
New York Presbyterian Hospital (Cornell Campus)
Residency • Internal Medicine
2009 - 2012
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 159 | 485 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 148 | 426 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 72 | 72 |
Adjuvant and Neoadjuvant Systemic Therapy for Pancreas Adenocarcinoma
Authors: Crook, Christiana, Zhang, Ya-Han, Li, Daneng
Journal: Drugs Aging
Publication Date: 2022-03-25
Lead Sponsor: City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Questionnaire Administration, OTHER: Quality-of-Life Assessment, OTHER: Survey Administration, OTHER: Comprehensive Geriatric Assessment
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Magnetic Resonance Imaging, PROCEDURE: Biospecimen Collection, PROCEDURE: Computed Tomography, DRUG: Cobimetinib, PROCEDURE: Biopsy, BIOLOGICAL: Atezolizumab, DRUG: Varlilumab
Lead Sponsor: Hutchmed
Collaborators: BeiGene
Intervention / Treatment: DRUG: Surufatinib and Tislelizumab _ Part 1, DRUG: Surufatinib and Tislelizumab _ Part 2